AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
AstraZeneca PLC News & Analysis
markets
What are emerging and frontier markets?
Power blocs, frontier stocks and investor shocks explained as the world becomes more complex
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
Best international companies to own: 2023 Edition
These companies from various corners of the globe are well positioned for the future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,137.80 | 14.90 | 0.16% |
CAC 40 | 7,872.02 | 41.91 | 0.54% |
DAX 40 | 23,611.33 | 84.28 | 0.36% |
Dow JONES (US) | 46,292.78 | 88.76 | -0.19% |
FTSE 100 | 9,223.32 | 3.36 | -0.04% |
HKSE | 26,159.12 | 185.02 | -0.70% |
NASDAQ | 22,573.47 | 215.50 | -0.95% |
Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
NZX 50 Index | 13,136.54 | 5.00 | -0.04% |
S&P 500 | 6,656.92 | 36.83 | -0.55% |
S&P/ASX 200 | 8,845.90 | 14.30 | 0.16% |
SSE Composite Index | 3,821.83 | 6.74 | -0.18% |